Skip to main content
NCBI home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2021 Dec 2;12:784712. doi: 10.3389/fphar.2021.784712

Meta-Analysis of NUDT15 Genetic Polymorphism on Thiopurine-Induced Myelosuppression in Asian Populations

Kanyarat Khaeso 1, Sariya Udayachalerm 2, Patcharee Komvilaisak 3, Su-on Chainansamit 4, Kunanya Suwannaying 3, Napat Laoaroon 3, Pitchayanan Kuwatjanakul 5, Nontaya Nakkam 1, Chonlaphat Sukasem 6,7, Apichaya Puangpetch 6,7, Wichittra Tassaneeyakul 1,*, Nathorn Chaiyakunapruk 2,*
PMCID: PMC8675242  PMID: 34925040

Abstract

Backgound: The high incidence of thiopurine-induced myelosuppression in Asians is known to be attributable to genetic variation in thiopurine metabolism. A quantitative synthesis to summarize the genetic association with thiopurine-induced myelosuppression in Asians was therefore conducted.

Methods: A Literature search was performed from January 2016 to May 2021 in the following databases: PubMed, Web of Science, and Embase and addition search included the studies from Zhang et al. Two reviewers independently extracted the following data: the author’s name, year of publication, ethnicity, drugs, diseases, genetic polymorphisms, onset, type of myelosuppression and results of Hardy-Weinberg equilibrium. The Newcastle-Ottawa Scale was used to assess the quality of the studies. The pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated to evaluate the associations of NUDT15 and the risk of thiopurine-induced myelosuppression stratified by onset and type of myelosuppressive. Subgroup analysis by NUDT15 genetic polymorphisms was performed.

Results: A total of 30 studies was included in this meta-analysis. The overall OR for the relationship between NUDT15 genetic polymorphisms and thiopurine-induced early onset of leukopenia and neutropenia in Asian populations were 11.43 (95% CI 7.11–18.35) and 16.35 (95% CI 10.20–26.22). Among NUDT15 polymorphisms, NUDT15*3 showed a significantly increased risk of early leukopenia (OR 15.31; 95% CI 9.65–24.27) and early neutropenia (OR 15.85; 95% CI 8.80–28.53). A significantly higher thiopurine-induced early neutropenic risk was also found for NUDT15*2 (OR 37.51; 95% CI 1.99–708.69). Whereas, NUDT15*5 and NUDT15*6 variants showed a lower risk of leukopenia.

Conclusion: This study suggests that NUDT15*3 and NUDT15*2 are important genetic markers of thiopurine-induced early onset of myelotoxicity in Asians, therefore, early detection of these variants before initiating thiopurine therapy is necessary.

Keywords: nucleoside diphosphate–linked moiety X-type motif 15 (NUDT15), thiopurine drugs, hematotoxicity, genetic polymorphism, precision medicine, Meta-analysis, Systematic review

Introduction

Thiopurines, 6-mercaptopurine (6-MP) and azathioprine (AZA), are purine analogs that are closely related in their structures (Coulthard and Hogarth, 2005). 6-MP is widely used in the treatment of acute lymphoblastic leukemia (ALL) as part of a combination regimen at the maintenance phase and used as an immunosuppressive agent for maintaining the remission of the disease. It is also prescribed off-label for the treatment of inflammatory bowel disease (IBD) (Dean, 2012). AZA is commonly used in management of autoimmune disorders e.g. Crohn’s disease, rheumatoid arthritis, and systemic lupus erythematosus (SLE) (Zaza et al., 2010), whereas thiopurine drugs have been shown to be effective in maintaining disease remission; however, almost 30–40% of patients discontinue therapy due to adverse effects, particularly myelosuppression (Lee et al., 2015), in which its incidence is higher in Asian populations than in Caucasian populations (Kakuta et al., 2018b). Thiopurine-induced myelosuppression often causes infectious complications and some patients require therapy interruption leading to suboptimal treatment and unfavorable outcomes (Relling et al., 1999; Hindorf et al., 2006). These adverse effects are known to be caused by individual differences in thiopurine metabolism, which is affected by the genetic variations.

6-MP is metabolized into inactive 6- methyl mercaptopurine (6-MMP) by Thiopurine S-methyltransferase (TPMT) (Lennard, 1992). It is well known that TPMT polymorphisms result in TPMT deficiency thereby increasing concentration of 6-thioguanine nucleotide (6-TGN) levels related to myelosuppression (Weinshilboum and Sladek, 1980). The frequencies of TPMT polymorphisms are ethnic differences which are higher in Caucasians than in the Asian population, which may explain the high incidence of thiopurine-induced myelosuppression in Asians (Collie-Duguid et al., 1999). Recently, several lines of evidence reported that the nucleoside diphosphate–linked moiety X-type motif 15 (NUDT15) was strongly associated with thiopurine-induced myelosuppression, specifically in Asian populations (Yang et al., 2014; Yang et al., 2015; Moriyama et al., 2016). The distribution of NUDT15 genetic polymorphism was reported to be the most common in East Asians, but rare in Caucasians (Yang et al., 2014; Yang et al., 2015; Moriyama et al., 2016). NUDT15 enzyme dephosphorylates 6-TGN then prevent the incorporation into DNA or RNA (Moriyama et al., 2016) therefore decreasing of the enzymatic activity which observed in NUDT15 variants, particularly NUDT15*3 was leading to thiopurine-induced myelosuppression (Moriyama et al., 2016).

Although the association between the NUDT15*3 variant and thiopurine-induced myelotoxicity is well recognized, there is still controversy about the increased risk of thiopurine hematotoxicity in patients who carry other variants of this gene, particularly NUDT15*2, NUDT15*5, NUDT15*6 which exist in high allele frequencies in Asian populations (Yang et al., 2014; Yang et al., 2015; Moriyama et al., 2016; Kim et al., 2017a). A quantitative synthesis of the existing genetic association studies to summarize the magnitude of the genetic association of all common variants of NUDT15 on thiopurine-induced toxicity was therefore conducted in order to ensure proper treatment and minimize the risk of thiopurine-induced myelosuppression in the Asian populations.

Methods

Data Sources and Search Strategy

A literature -search was conducted using PubMed, Web of Science, and Embase. Searches were performed using keywords and synonyms for NUDT15 and thiopurines and relevant terms for myelosuppression. MeSH terms in PubMed were used when available. There was no language or study design restriction, but only human studies were included. In the present meta-analysis, an updated search included the studies from Zhang et al., the previously systematic review and meta-analysis (Zhang et al., 2018), and additional studies published between January 1, 2016 and May 14, 2021.

Study Selection

Two reviewers (KK and WT) independently assessed abstracts and titles retrieved from the comprehensive searches for study inclusion. Articles from the updated search and from Zhang et al. were included if they met the inclusion criteria, as follows: 1) the study population was of patients treated with thiopurine drugs: 6-MP, AZA or 6-TG 2) Studied the association between genetic polymorphisms of NUDT15 and thiopurine-induced myelosuppression in an Asian population 3) the outcomes of interest included myelosuppression (anemia, neutropenia, leukopenia, and thrombocytopenia) 4) the study provided sufficient information to calculate the genetic association with thiopurine-induced myelosuppression. Exclusion criteria are 1) studies not relevant to pharmacogenetic of NUDT15 and TPMT and thiopurine-induced toxicity in Asian; 2) not clinical study; 3) review study, systematic review, meta-analysis, letters, editorials, opinion, commentaries, case report; 4) no full text available; 5) not report odds ratio or no sufficient information for calculate odd ratio or data not related to dose reduction. Any disagreements were discussed until consensus between the two reviewers could be reached.

Data Extraction and Quality Assessment

Data extraction was performed by two independent reviewers. Any disagreement was discussed and the data checked again to arrive at an agreement. The following data were extracted from each study: the first author’s last name, year of publication, ethnicity, drugs used, disease type, genetic polymorphisms, onset and type of myelosuppression. The Hardy-Weinberg equilibrium (HWE) was tested to check if the included individuals were in equilibrium for the frequencies of genotypes (Salanti et al., 2005; Mayo, 2008). Equilibrium implies that the included individuals were likely representative of the population (Smits et al., 2005; Thakkinstian et al., 2005). The quality of the selected studies was evaluated using the Newcastle–Ottawa Scale (NOS) (Wells et al., 2014). This scale is an 8-item instrument, categorized into the following three domains: selection of participants, comparability between groups, and the assessment of exposures and outcomes. A system of stars was used to provide quality ratings for studies.

Statistical Analysis

The pooled odd ratio (OR) and 95% CI were calculated to determine the association between genetic polymorphisms and the risk of thiopurine-induced myelosuppression. All analyses were performed with the method by DerSimonian and Laird (DerSimonian and Laird, 1986) using a random-effects model. Subgroup analysis was performed based on NUDT15 variants. Statistical heterogeneity was assessed via the Q statistic and I2 tests (Higgins and Thompson, 2002). p ≤ 0.10 indicated heterogeneity between studies. I2 values of 25 and 50% denoted low heterogeneity and moderate heterogeneity, across studies (Higgins et al., 2003). The Funnel plot, Begg test, and Egger test were used to evaluate small study effect (Begg and Berlin, 1989). All analyses were performed in STATA version 13.0 (StataCorp, College Station, Texas, USA).

Results

Study Selection

A total of 431 studies were identified from an updated literature search while an additional seven studies from a previous systematic meta-analysis by Zhang et al. (2018) were reviewed. Of the original 431 articles, 30 studies were included in the meta-analysis. No additional articles were identified via a review of the bibliographies of the included studies. (Figure 1).

FIGURE 1.

FIGURE 1

Open in a new tab

Study selection process.

Study Characteristics

Characteristics of 30 studies are described in Table 1. All studies were conducted among Asians populations. There were 1,167 cases with leukopenia and 240 cases with neutropenia. Among these, 14 studies were conducted in IBD (Yang et al., 2014; Asada et al., 2016; Kakuta et al., 2016; Zhu et al., 2016; Chao et al., 2017; Sato et al., 2017; Shah et al., 2017; Kakuta et al., 2018a; Sutiman et al., 2018; Wang et al., 2018; Akiyama et al., 2019; Banerjee et al., 2020; Kang et al., 2020; Xu et al., 2020), nine studies in ALL (Tanaka et al., 2015; Chiengthong et al., 2016; Tanaka et al., 2018; Zhou et al., 2018; Buaboonnam et al., 2019; Choi et al., 2019; Kodidela et al., 2020; Puangpetch et al., 2020; Ramalingam et al., 2021) and seven studies in other autoimmune diseases (autoimmune hepatitis, dermatological diseases and rheumatological diseases) (Kim et al., 2017b; Fei et al., 2018; Yang et al., 2019a; Fan et al., 2019; Huang et al., 2020; Su et al., 2020; Miao et al., 2021).

TABLE 1.

Characteristics of all analyses.

Source Nationality Disease type Sample size Drug SNP Toxic criteria Onset Myelosup pression type No. positive for genetic variation/Total no.
Case Control
Yang et al. (2014) Korean Crohn’s disease 978 AZA NUDT15*3 WBC <3,000 cells/mm3 within 8 weeks Early leukopenia 59/66 131/912
WBC <3,000 cells/mm3 after the first 8 weeks Late leukopenia 88/280 102/698
Tanaka et al. (2015) Japanese ALL 92 6-MP NUDT15*3 WBC <2 × 109/L within first 60 days Early leukopenia 10/22 14/70
Asada et al. (2016) Japanese IBD 161 AZA/6-MP NUDT15*3 WBC <3,000/uL within 8 weeks Early leukopenia 4/6 30/115
WBC <3,000/uL after the first 8 weeks Late leukopenia 16/39 14/116
Chiengthong et al. (2016) Thai ALL 82 6-MP NUDT15*3 ANC <500 cells/µL at month 2 Early neutropenia 3/6 9/76
NUDT15*3 ANC <500 cells/µL at month 4 Late neutropenia 9/21 3/61
Kakuta et al. (2016) Japanese IBD 135 AZA/6-MP NUDT15*3 WBC <3,000 mm−3 within 8 weeks Early leukopenia 9/10 19/125
WBC <3,000 mm−3 after 8 weeks Late leukopenia 6/24 12/87
Zhu et al. (2016) Han Chinese CD 253 AZA/6-MP NUDT15*3 WBC <3.5 × 109/L 0–8 weeks Early leukopenia 19/27 38/226
WBC <3.5 × 109/L 8–24 weeks Late leukopenia 16/22 41/231
Chao et al. (2017) Han Chinese IBD 732 AZA/6-MP NUDT15*3 WBC <3,500 mm−3 0–8 weeks Early leukopenia 43/70 132/662
WBC <3,500 mm−3 8–24 weeks Late leukopenia 23/43 152/689
NUDT15*6 WBC <3,500 mm−3 0–8 weeks Early leukopenia 18/70 66/662
WBC <3,500 mm−3 8–24 weeks Late leukopenia 10/43 74/689
NUDT15*5 WBC <3,500 mm−3 0–8 weeks Early leukopenia 6/70 11/662
WBC <3,500 mm−3 8–24 weeks Late leukopenia 2/43 15/689
Kim et al. (2017b) Korean Neuro immunological diseases 92 AZA NUDT15*3 WBC <3,500 cells/μl within 8 weeks Early leukopenia 6/7 7/77
WBC <3,500 cells/μl after 8 weeks Late leukopenia 2/13 11/71
Sato et al. (2017) Japanese CD, UC, IBD unclassified, or intestinal Behçet disease 160 AZA/6-MP NUDT15*3 WBC <3,000/μL within 8 weeks Early leukopenia 13/16 27/133
WBC <3,000/μL after 8 weeks Late leukopenia 17/43 23/106
NUDT15*6 WBC <3,000/μL within 8 weeks Early leukopenia 2/16 8/133
WBC <3,000/μL after 8 weeks Late leukopenia 5/43 5/106
NUDT15*5 WBC <3,000/μL within 8 weeks Early leukopenia 0/16 2/133
WBC <3,000/μL after 8 weeks Late leukopenia 2/43 0/106
Shah et al. (2017) Indian UC, CD, AIH 69 AZA/6-MP NUDT15*3 WBC <3,000/mm3 within 8 weeks Early leukopenia 4/4 5/65
WBC <3,000/mm3 after 8 weeks Late leukopenia 2/2 7/67
Fei et al. (2018) Chinese Auto-immune diseases 87 AZA NUDT15*3 WBC <3.5 × 109/L before 8 weeks Early leukopenia 17/21 11/66
WBC <3.5 × 109/L after 8 weeks Late leukopenia 1/2 27/86
Kakuta et al. (2018a) Japanese CD, UC, or BD 2,627 AZA/6-MP NUDT15*3 WBC <3,000/lL <8 weeks Early leukopenia 66/80 258/1,202
Sutiman et al. (2018) Asians (Chinese, Indian, Malay, others) IBD 129 AZA/6-MP NUDT15*3 WBC <3 × 109/L NA Leukopenia 7/10 11/119
ANC <1.5 × 109/L NA Neutropenia 6/10 12/119
NUDT15*6 WBC <3 × 109/L NA Leukopenia 3/10 8/119
ANC <1.5 × 109/L NA Neutropenia 2/10 9/119
Tanaka et al. (2018) Japanese ALL 95 6-MP NUDT15*3 WBC <2.0 × 109/L NA Leukopenia 19/38 6/57
NUDT15*5 WBC <2.0 × 109/L NA Leukopenia 4/38 1/57
Wang et al. (2018) Chinese IBD 219 AZA NUDT15*3 WBC <3.5 × 109/L NA Leukopenia 8/19 8/61
Zhou et al. (2018) Chinese ALL 105 6-MP NUDT15*3 WBC <2 × 109/L during the first 60 days Early leukopenia 11/15 20/90
Akiyama et al. (2019) Japanese IBD 83 AZA/6-MP NUDT15*3 WBC <3,000/mm3 NA Leukopenia 11/18 10/63
Buaboonnam et al. (2019) Thai ALL 102 6-MP NUDT15*3 ANC <500/mm3 at 3 months Late neutropenia 12/18 12/84
Choi et al. (2019) Korean ALL 139 6-MP NUDT15*3 WBC <1.5 × 109 L−1 NA Leukopenia 5/7 25/132
ANC <0.5 × 109 L−1 NA Neutropenia 3/4 27/132
Fan et al. (2019) Chinese AIH 149 AZA NUDT15*3 WBC <3 × 109/L during first 8 weeks Early leukopenia 11/12 15/137
Yang et al. (2019a) Han Chinese Auto-immune diseases 86 AZA NUDT15*3 WBC <3.5 × 109/L NA Leukopenia 11/19 7/67
NUDT15*5 WBC <3.5 × 109/L NA Leukopenia 0/19 3/67
NUDT15*6 WBC <3.5 × 109/L NA Leukopenia 3/19 2/67
Huang et al. (2020) Han Chinese Dermatological diseases 56 AZA NUDT15*3 ANC <1,500/mm3 within 8 weeks Early neutropenia 5/7 15/49
ANC <1,500/mm3 after 8 weeks Late neutropenia 3/5 17/51
Kang et al. (2020) Korean IBD 167 AZA NUDT15*3 WBC <3,000/μL NA Leukopenia 13/32 14/114
NUDT15*5 WBC <3,000/μL NA Leukopenia 2/21 3/103
NUDT15*6 WBC <3,000/μL NA Leukopenia 1/20 0/100
Kodidela et al. (2020) South Indian ALL 73 6-MP NUDT15*3 grade 3–4 within the first 100 days Early leukopenia 12/39 2/32
hematological toxicities
Puangpetch et al. (2020) Thai ALL 100 6-MP NUDT15*2 ANC <500/mm3 weeks 1–8 Early neutropenia 5/24 0/66
ANC <500/mm3 weeks 9–24 Late neutropenia 2/41 3/49
NUDT15*3 ANC <500/mm3 weeks 1–8 Early neutropenia 3/22 1/67
ANC <500/mm3 weeks 9–24 Late neutropenia 0/39 4/50
NUDT15*6 ANC <500/mm3 weeks 1–8 Early neutropenia 4/23 2/68
ANC <500/mm3 weeks 9–24 Late neutropenia 6/45 0/46
Banerjee et al. (2020) Indian IBD 935 AZA NUDT15*3 WBC <3 × 109/L NA Leukopenia 54/81 80/854
ANC <1.5 × 109/L NA Neutropenia 49/70 85/865
Su et al. (2020) Chinese Rheumatological disease 70 AZA NUDT15*3 WBC <3.5 × 109/L NA Leukopenia 13/28 6/42
Xu et al. (2020) Chinese IBD 159 AZA NUDT15*3 WBC <3.5 × 109/L NA Leukopenia 14/37 19/122
Miao et al. (2021) Chinese AIH 113 AZA NUDT15*3 WBC <4 × 109/L NA Leukopenia 9/15 16/98
ANC <2 × 109/L NA Neutropenia 7/10 18/103
Ramalingam et al. (2021) South Indian ALL 127 6-MP NUDT15*3 ANC <2000 cells/mm3 NA Neutropenia 7/28 5/99
Open in a new tab

Note: WBC, white blood cell; ANC, absolute neutrophil count; NA, not available. SNP, it is not a value. It is the name of gene and according to the nomenclature of genes, italic text should be used.

Myelosuppression was categorized based on the onset and characteristics of blood cell type, including of leukopenia and neutropenia. The onset of myelosuppression within 8 weeks was defined as early whereas the onset after 8 weeks was defined as late. For those studies without a clear description of onset of myelosuppression, the onset was classified based on duration of the study. Among studies conducted in ALL patients, the 6-MP dose was 40–75 mg/m2/d, while the studies conducted in IBD or autoimmune diseases was AZA 0.5–3 mg/kg/d. The distribution of observed alleles and expected alleles of each genetic variation were consistent with HWE, except for three studies (Tanaka et al., 2015; Kakuta et al., 2018a; Tanaka et al., 2018).

Quality Assessment

The methodological quality of all studies is summarized as a mean Newcastle-Ottawa Scale score of 8 (range, 7–9; maximum score, 9, see Supplementary Table S2).

Quantitative Synthesis

Association between genetic polymorphisms involved in thiopurine metabolism and risk of myelosuppression.

NUDT15*3 Polymorphisms (rs116855232)

In thirty studies with NUDT15*3, there were 476 cases with early leukopenia from 15 studies, 691 cases with late leukopenia from 19 studies. Of these, 338 cases (71%) with early onset and 281 cases (40.67%) with late onset carried the NUDT15*3 variant. The higher risk for development of early leukopenia was found to be significantly associated with NUDT15*3 carriers (OR 15.31; 95% CI 9.65–24.27, I2 = 63.6%) (Figure 2) compared to those patients with late onset (OR 4.9; 95% CI 3.56–6.74, I2 = 47.4) (Supplementary Figure S1). In addition, there were 105 cases with early neutropenia. Of these, 60 cases (57.14%) carried NUDT15*3. The study also found a strong relationship between NUDT15*3 and risk of early neutropenia in studied patients (OR 15.85; 95% CI 8.8–28.53, I2 7.4%, p = 0.356) (Figure 3).

FIGURE 2.

FIGURE 2

Open in a new tab

The forest plots for the association of NUDT15 variants with thiopurine-induced early leukopenia. Note: Width of the box indicates the precision of the estimates; diamond, the overall summary estimate for the analysis (width of the diamond represents the 95% CI).

FIGURE 3.

FIGURE 3

Open in a new tab

The forest plots for the association of NUDT15 variants with thiopurine-induced early neutropenia. Note: Width of the box indicates the precision of the estimates; diamond, the overall summary estimate for the analysis (width of the diamond represents the 95% CI).

NUDT15*5 (rs186364861), NUDT15*6 (rs869320766) and NUDT15*2 (rs116855232, rs869320766)

Six studies were included to determine the association of NUDT15*5 and NUDT15*6 with the risk of myelosuppression. Overall, with those who carried either NUDT15*5 or NUDT15*6, 15.12% (26 of 172) cases had early leukopenia whereas 10.70% (32 of 299) cases had late leukopenia. For neutropenia, 17.39% (4 of 23) cases with early onset and 14.55% (8 of 55) cases with late onset carried NUDT15*6. The OR for early and late leukopenia was about 3.01–4.9 for NUDT15*5 and NUDT15*6 variants (Figure 2, Supplementary Figure S1). Only one study showed a significant 6.95-fold higher risk for NUDT15*6 variant carriers to develop early neutropenia (OR 6.95; 95% CI 1.18–40.89) (Figure 3). There was one study reporting the significant association between NUDT15*2 and early neutropenia in ALL patients (OR 37.51; 95% CI 1.99–708.69) (Figure 3) but not for late neutropenia (Supplementary Figure S2).

Small Study Effect

Begg’s and Egger’s test were performed to assess for small study effect. The Egger’s test and Begg’s test were not significant for all analysis (p > 0.05, see Supplementary Table S1), except for late neutropenia. However, no asymmetry was found in the funnel plot indicating a lack of evidence for a small study effect (see Supplementary Figures S3–6).

Discussion

Recently, a number of studies suggested that NUDT15*3 was a novel predictor of thiopurine-induced myelosuppression in Asians (Yang et al., 2014; Yang et al., 2015; Moriyama et al., 2016). To date, more than 20 variants of the NUDT15 gene have been reported (Yang et al., 2019b). The common variant alleles are NUDT15*2 (rs869320766; c.36_37insGGAGTC and rs116855232; c.415C > T), NUDT15*3 (rs116855232; c.415C > T), NUDT15*5 (rs186364861; c.52G > A), and NUDT15*6 (rs869320766; c.36_37insGGAGTC) (Moriyama et al., 2016) in which NUDT13*3 is the most prevalent in Asian populations (Yang et al., 2014; Yang et al., 2015; Moriyama et al., 2016; Kim et al., 2017a; Khaeso et al., 2021). This current study’s results indicate that the overall OR for the relationship between NUDT15 genetic polymorphisms and thiopurine-induced early onset of leukopenia and neutropenia were 11.43 (95%CI 7.11–18.35) and 16.35 (95% CI 10.20–26.22). The higher risk was noted in patients who carried NUDT15*3 more than any other variant with an OR of 15.31 for early leukopenia and 15.85 for early neutropenia. In addition, an almost 38-fold increase of risk of early neutropenia was also found for NUDT15*2 carrier patients.

NUDT15*3 and NUDT15*2 showed a 100% loss of enzyme activity (Moriyama et al., 2016). The recent Clinical Implementation Consortium (CPIC) Guidelines for Thiopurine classified an individual carrying one normal function allele with NUDT15*2 or NUDT15*3 allele as an intermediate metabolizer whereas an individual carrying these two no function alleles were poor metabolizers (Relling and Schwab, 2019). It has been reported that patients with NUDT15*1/*2 which contain both rs869320766 and rs116855232 had a similar degree of 6-MP intolerance as the NUDT15*1/*3 (which contained a single rs116855232 SNP) (Moriyama et al., 2016). A similar result was reported in that the NUDT15*2 variant showed an approximate 38-fold higher risk of early neutropenia in ALL patients who were treated with 6-MP (Puangpetch et al., 2020). This suggested that these two variants of NUDT15 proteins may have exhibited similar enzymatic activity (Moriyama et al., 2016).

Unlike NUDT15*3 and NUDT15*2, an in vitro study reported that NUDT15*5 and NUDT15*6 showed a loss of enzyme activity of about 50–60%, however, in vivo activities of these enzymes were not quite clear (Moriyama et al., 2016). Previous studies showed controversy about the increased risk of thiopurine hematotoxicity in patients who carried these variant alleles, particularly NUDT15*6 (Sato et al., 2017; Sutiman et al., 2018; Tanaka et al., 2018). The previous meta-analysis has reported a lower diagnostic accuracy for NUDT15*6 and NUDT15*5 compared to NUDT15*3 (Cargnin et al., 2018), consistent with the current results that revealed a lower risk of OR in patients who carried NUDT15*5 or NUDT15*6 with the risk of myelosuppression compared to NUDT15*3.

The results from this meta-analysis showed that the lower number of OR was found in late onset of myelosuppression and that these may be because thiopurine toxicity often occurs in the first few months of the maintenance phase. The reason may be due to the fact that practically, the thiopurine dose was gradually adjusted to the tolerated dose which resulted in no myelosuppressive effect. Therefore NUDT15*3 polymorphism had the increased risk of thiopurine-induced leukopenia and neutropenia in particular, as early as the first 2 months of the maintenance phase of treatment.

One limitation that deserves discussion is a significant heterogeneity observed amongst studies evaluating the association between with NUDT15*3 carriers and early leukopenia. We could not explore the cause of this heterogeneity. Despite the fact that we used a random-effects model to pool the results across studies, the results of the meta-analysis for early leukopenia should be interpreted with caution.

Conclusion

In summary, this study found a strong relationship between NUDT15*3 and NUDT15*2 variants and thiopurine-induced early onset myelosuppression. The rs116855232 SNP which exists in both of these variants appears to be a key SNP for thiopurine-induced hematoxtoxicity. The genotyping of the rs116855232 which has a high prevalence in Asian populations should be considered prior prescribing thiopurine drugs in order to predict the risk of early myelosuppression.

Acknowledgments

We would like to acknowledge Prof. James A. Will, University of Wisconsin-Madison, for critical review and editing the manuscript via Publication Clinic KKU, Thailand.

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author Contributions

KK, SU, NC, and WT study design. KK and SU search strategy and literature search. KK and WT data extraction. KK, SU, and NC data analysis, assessment of study quality and risk of bias. All authors contributed to manuscript drafting and final approval of the manuscript.

Funding

This work was supported by grants from the Health System Research Institute (under Genomics Thailand Strategic Fund, HSRI 64–082), Faculty of Medicine, Khon Kaen University, Thailand (grant number IN64111) and the scholarship support from the Graduate School, Khon Kaen University through the Research Fund for Supporting Lecturers to Admit High Potential Student to Study and Research on His Expert Program Year 2019 (grant number 621H219).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.784712/full#supplementary-material

Click here for additional data file. (801.3KB, docx)

References

  1. Akiyama S., Matsuoka K., Fukuda K., Hamada S., Shimizu M., Nanki K., et al. (2019). Long-term Effect of NUDT15 R139C on Hematologic Indices in Inflammatory Bowel Disease Patients Treated with Thiopurine. J. Gastroenterol. Hepatol. 34, 1751–1757. 10.1111/jgh.14693 [DOI] [PubMed] [Google Scholar]
  2. Asada A., Nishida A., Shioya M., Imaeda H., Inatomi O., Bamba S., et al. (2016). NUDT15 R139C-Related Thiopurine Leukocytopenia Is Mediated by 6-thioguanine Nucleotide-independent Mechanism in Japanese Patients with Inflammatory Bowel Disease. J. Gastroenterol. 51, 22–29. 10.1007/s00535-015-1142-4 [DOI] [PubMed] [Google Scholar]
  3. Banerjee R., Ravikanth V. V., Pal P., Bale G., Avanthi U. S., Goren I., et al. (2020). NUDT15 C415T Variant Compared with TPMT Genotyping in Predicting Azathioprine-Induced Leucopenia: Prospective Analysis of 1014 Inflammatory Bowel Disease Patients in India. Aliment. Pharmacol. Ther. 52, 1683–1694. 10.1111/apt.16137 [DOI] [PubMed] [Google Scholar]
  4. Begg C. B., Berlin J. A. (1989). Publication Bias and Dissemination of Clinical Research. J. Natl. Cancer Inst. 81, 107–115. 10.1093/jnci/81.2.107 [DOI] [PubMed] [Google Scholar]
  5. Buaboonnam J., Sripatanatadasakul P., Treesucon A., Glomglao W., Siraprapapat P., Narkbunnam N., et al. (2019). Effect of NUDT15 on Incidence of Neutropenia in Children with Acute Lymphoblastic Leukemia. Pediatr. Int. 61, 754–758. 10.1111/ped.13905 [DOI] [PubMed] [Google Scholar]
  6. Cargnin S., Genazzani A. A., Canonico P. L., Terrazzino S. (2018). Diagnostic Accuracy of NUDT15 Gene Variants for Thiopurine-Induced Leukopenia: a Systematic Review and Meta-Analysis. Pharmacol. Res. 135, 102–111. 10.1016/j.phrs.2018.07.021 [DOI] [PubMed] [Google Scholar]
  7. Chao K., Wang X., Cao Q., Qian J., Wu K., Zhu X., et al. (2017). Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-Induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: a Multicenter Analysis. Inflamm. Bowel Dis. 23, 1592–1599. 10.1097/MIB.0000000000001148 [DOI] [PubMed] [Google Scholar]
  8. Chiengthong K., Ittiwut C., Muensri S., Sophonphan J., Sosothikul D., Seksan P., et al. (2016). NUDT15 c.415C>T Increases Risk of 6-mercaptopurine Induced Myelosuppression during Maintenance Therapy in Children with Acute Lymphoblastic Leukemia. Haematologica 101, e24–6. 10.3324/haematol.2015.134775 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Choi R., Sohn I., Kim M. J., Woo H. I., Lee J. W., Ma Y., et al. (2019). Pathway Genes and Metabolites in Thiopurine Therapy in Korean Children with Acute Lymphoblastic Leukaemia. Br. J. Clin. Pharmacol. 85, 1585–1597. 10.1111/bcp.13943 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Collie-Duguid E. S., Pritchard S. C., Powrie R. H., Sludden J., Collier D. A., Li T., et al. (1999). The Frequency and Distribution of Thiopurine Methyltransferase Alleles in Caucasian and Asian Populations. Pharmacogenetics 9, 37–42. 10.1097/00008571-199902000-00006 [DOI] [PubMed] [Google Scholar]
  11. Coulthard S., Hogarth L. (2005). The Thiopurines: an Update. Invest. New Drugs 23, 523–532. 10.1007/s10637-005-4020-8 [DOI] [PubMed] [Google Scholar]
  12. Dean L. (2012). “Mercaptopurine Therapy and TPMT Genotype,” in Medical Genetics Summaries. Editors Pratt V. M., McLeod H. L., Rubinstein W. S., Scott S. A., Dean L. C., Kattman B. L., et al. (Bethesda (MD). [Google Scholar]
  13. DerSimonian R., Laird N. (1986). Meta-analysis in Clinical Trials. Control. Clin. Trials 7, 177–188. 10.1016/0197-2456(86)90046-2 [DOI] [PubMed] [Google Scholar]
  14. Fan X., Yin D., Men R., Xu H., Yang L. (2019). NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients with Autoimmune Hepatitis and Related Cirrhosis. Front. Pharmacol. 10, 346. 10.3389/fphar.2019.00346 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fei X., Shu Q., Zhu H., Hua B., Wang S., Guo L., et al. (2018). NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients. Front. Pharmacol. 9, 460. 10.3389/fphar.2018.00460 [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Higgins J. P., Thompson S. G., Deeks J. J., Altman D. G. (2003). Measuring Inconsistency in Meta-Analyses. BMJ 327, 557–560. 10.1136/bmj.327.7414.557 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Higgins J. P., Thompson S. G. (2002). Quantifying Heterogeneity in a Meta-Analysis. Stat. Med. 21, 1539–1558. 10.1002/sim.1186 [DOI] [PubMed] [Google Scholar]
  18. Hindorf U., Lindqvist M., Hildebrand H., Fagerberg U., Almer S. (2006). Adverse Events Leading to Modification of Therapy in a Large Cohort of Patients with Inflammatory Bowel Disease. Aliment. Pharmacol. Ther. 24, 331–342. 10.1111/j.1365-2036.2006.02977.x [DOI] [PubMed] [Google Scholar]
  19. Huang P. W., Tseng Y. H., Tsai T. F. (2020). Predictive Value of NUDT15 Variants on Neutropenia Among Han Chinese Patients with Dermatologic Diseases: A Single-center Observational Study. Dermatol. Ther. (Heidelb) 10, 263–271. 10.1007/s13555-020-00360-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kakuta Y., Kawai Y., Okamoto D., Takagawa T., Ikeya K., Sakuraba H., et al. (2018a). NUDT15 Codon 139 Is the Best Pharmacogenetic Marker for Predicting Thiopurine-Induced Severe Adverse Events in Japanese Patients with Inflammatory Bowel Disease: a Multicenter Study. J. Gastroenterol. 53, 1065–1078. 10.1007/s00535-018-1486-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kakuta Y., Kinouchi Y., Shimosegawa T. (2018b). Pharmacogenetics of Thiopurines for Inflammatory Bowel Disease in East Asia: Prospects for Clinical Application of NUDT15 Genotyping. J. Gastroenterol. 53, 172–180. 10.1007/s00535-017-1416-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kakuta Y., Naito T., Onodera M., Kuroha M., Kimura T., Shiga H., et al. (2016). NUDT15 R139C Causes Thiopurine-Induced Early Severe Hair Loss and Leukopenia in Japanese Patients with IBD. Pharmacogenomics J. 16, 280–285. 10.1038/tpj.2015.43 [DOI] [PubMed] [Google Scholar]
  23. Kang B., Kim T. J., Choi J., Baek S. Y., Ahn S., Choi R., et al. (2020). Adjustment of Azathioprine Dose Should Be Based on a Lower 6-TGN Target Level to Avoid Leucopenia in NUDT15 Intermediate Metabolisers. Aliment. Pharmacol. Ther. 52, 459–470. 10.1111/apt.15810 [DOI] [PubMed] [Google Scholar]
  24. Khaeso K., Nakkam N., Komwilaisak P., Wongmast P., Chainansamit S. O., Dornsena A., et al. (2021). Genetic Polymorphisms of Drug-Metabolizing Enzymes Involved in 6-Mercaptopurine-Induced Myelosuppression in Thai Pediatric Acute Lymphoblastic Leukemia Patients. J. Pediatr. Genet. 10, 29–34. 10.1055/s-0040-1715818 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kim H. T., Choi R., Won H. H., Choe Y. H., Kang B., Lee K., et al. (2017a). NUDT15 Genotype Distributions in the Korean Population. Pharmacogenet Genomics 27, 197–200. 10.1097/FPC.0000000000000274 [DOI] [PubMed] [Google Scholar]
  26. Kim S. Y., Shin J. H., Park J. S., Kang S. Y., Nam T. S., Kim J. K., et al. (2017b). NUDT15 p.R139C Variant Is Common and Strongly Associated with Azathioprine-Induced Early Leukopenia and Severe Alopecia in Korean Patients with Various Neurological Diseases. J. Neurol. Sci. 378, 64–68. 10.1016/j.jns.2017.04.041 [DOI] [PubMed] [Google Scholar]
  27. Kodidela S., Dorababu P., Thakkar D. N., Dubashi B., Sundaram R., Muralidharan N., et al. (2020). Association of NUDT15*3 and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity during 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia. Genes (Basel) 11. 10.3390/genes11060594 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lee K. M., Kim Y. S., Seo G. S., Kim T. O., Yang S. K. IBD Study Group of the Korean Association for the Study of Intestinal Diseases (2015). Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 13, 193–207. 10.5217/ir.2015.13.3.193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lennard L. (1992). The Clinical Pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43, 329–339. 10.1007/BF02220605 [DOI] [PubMed] [Google Scholar]
  30. Mayo O. (2008). A century of Hardy-Weinberg Equilibrium. Twin Res. Hum. Genet. 11, 249–256. 10.1375/twin.11.3.249 [DOI] [PubMed] [Google Scholar]
  31. Miao Q., Yan L., Zhou Y., Li Y., Zou Y., Wang L., et al. (2021). Association of Genetic Variants in TPMT, ITPA, and NUDT15 with Azathioprine-Induced Myelosuppression in Southwest china Patients with Autoimmune Hepatitis. Sci. Rep. 11, 7984. 10.1038/s41598-021-87095-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Moriyama T., Nishii R., Perez-Andreu V., Yang W., Klussmann F. A., Zhao X., et al. (2016). NUDT15 Polymorphisms Alter Thiopurine Metabolism and Hematopoietic Toxicity. Nat. Genet. 48, 367–373. 10.1038/ng.3508 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Puangpetch A., Tiyasirichokchai R., Pakakasama S., Wiwattanakul S., Anurathapan U., Hongeng S., et al. (2020). NUDT15 Genetic Variants Are Related to Thiopurine-Induced Neutropenia in Thai Children with Acute Lymphoblastic Leukemia. Pharmacogenomics 21, 403–410. 10.2217/pgs-2019-0177 [DOI] [PubMed] [Google Scholar]
  34. Ramalingam R., Kaur H., Scott J. X., Sneha L. M., Arun Kumar G. P., Srinivasan A., et al. (2021). Pharmacogenetic Evaluation of 6-Mercaptopurine-Mediated Toxicity in Pediatric Acute Lymphoblastic Leukemia Patients from a South Indian Population. Pharmacogenomics 22, 401–411. 10.2217/pgs-2020-0193 [DOI] [PubMed] [Google Scholar]
  35. Relling M. V., Hancock M. L., Boyett J. M., Pui C. H., Evans W. E. (1999). Prognostic Importance of 6-mercaptopurine Dose Intensity in Acute Lymphoblastic Leukemia. Blood 93, 2817–2823. 10.1182/blood.v93.9.2817.409k04_2817_2823 [DOI] [PubMed] [Google Scholar]
  36. Relling M. V., Schwab M., Whirl-Carrillo M., Suarez-Kurtz G., Pui C. H., Stein C. M., et al. (2019). Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin. Pharmacol. Ther. 105, 1095–1105. 10.1002/cpt.1304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Salanti G., Sanderson S., Higgins J. P. (2005). Obstacles and Opportunities in Meta-Analysis of Genetic Association Studies. Genet. Med. 7, 13–20. 10.1097/01.gim.0000151839.12032.1a [DOI] [PubMed] [Google Scholar]
  38. Sato T., Takagawa T., Kakuta Y., Nishio A., Kawai M., Kamikozuru K., et al. (2017). NUDT15, FTO, and RUNX1 Genetic Variants and Thiopurine Intolerance Among Japanese Patients with Inflammatory Bowel Diseases. Intest Res. 15, 328–337. 10.5217/ir.2017.15.3.328 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Shah S. A., Paradkar M., Desai D., Ashavaid T. F. (2017). Nucleoside Diphosphate-Linked Moiety X-type Motif 15 C415T Variant as a Predictor for Thiopurine-Induced Toxicity in Indian Patients. J. Gastroenterol. Hepatol. 32, 620–624. 10.1111/jgh.13494 [DOI] [PubMed] [Google Scholar]
  40. Smits K. M., Schouten J. S., Smits L. J., Stelma F. F., Nelemans P., Prins M. H. (2005). A Review on the Design and Reporting of Studies on Drug-Gene Interaction. J. Clin. Epidemiol. 58, 651–654. 10.1016/j.jclinepi.2005.01.001 [DOI] [PubMed] [Google Scholar]
  41. Su S. S., Lin Y. F., Zhou H. (2020). Association of Thiopurine S-Methyltransferase and NUDT15 Polymorphisms with Azathioprine-Induced Myelotoxicity in Chinese Patients with Rheumatological Disease. Chin. Med. J. (Engl) 133, 1002–1004. 10.1097/CM9.0000000000000756 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Sutiman N., Chen S., Ling K. L., Chuah S. W., Leong W. F., Nadiger V., et al. (2018). Predictive Role of NUDT15 Variants on Thiopurine-Induced Myelotoxicity in Asian Inflammatory Bowel Disease Patients. Pharmacogenomics 19, 31–43. 10.2217/pgs-2017-0147 [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Tanaka Y., Kato M., Hasegawa D., Urayama K. Y., Nakadate H., Kondoh K., et al. (2015). Susceptibility to 6-MP Toxicity Conferred by a NUDT15 Variant in Japanese Children with Acute Lymphoblastic Leukaemia. Br. J. Haematol. 171, 109–115. 10.1111/bjh.13518 [DOI] [PubMed] [Google Scholar]
  44. Tanaka Y., Nakadate H., Kondoh K., Nakamura K., Koh K., Manabe A. (2018). Interaction between NUDT15 and ABCC4 Variants Enhances Intolerability of 6-mercaptopurine in Japanese Patients with Childhood Acute Lymphoblastic Leukemia. Pharmacogenomics J. 18, 275–280. 10.1038/tpj.2017.12 [DOI] [PubMed] [Google Scholar]
  45. Thakkinstian A., McElduff P., D'Este C., Duffy D., Attia J. (2005). A Method for Meta-Analysis of Molecular Association Studies. Stat. Med. 24, 1291–1306. 10.1002/sim.2010 [DOI] [PubMed] [Google Scholar]
  46. Wang H. H., He Y., Wang H. X., Liao C. L., Peng Y., Tao L. J., et al. (2018). Comparison of TPMT and NUDT15 Polymorphisms in Chinese Patients with Inflammatory Bowel Disease. World J. Gastroenterol. 24, 941–948. 10.3748/wjg.v24.i8.941 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Weinshilboum R. M., Sladek S. L. (1980). Mercaptopurine Pharmacogenetics: Monogenic Inheritance of Erythrocyte Thiopurine Methyltransferase Activity. Am. J. Hum. Genet. 32, 651–662. [PMC free article] [PubMed] [Google Scholar]
  48. Wells G., Shea B., O'Connell D., Peterson J., Welch V., Losos M., et al. (2014). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses [Online]. Ottawa Hospital Research Institutewebsite. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (Accessed March 22, 2021). [Google Scholar]
  49. Xu Y., Qiao Y. Q., Li H. Y., Zhou M., Cai C. W., Shen J., et al. (2020). NUDT15 Genotyping during Azathioprine Treatment in Patients with Inflammatory Bowel Disease: Implications for a Dose-Optimization Strategy. Gastroenterol. Rep. (Oxf) 8, 437–444. 10.1093/gastro/goaa021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Yang J., Wang P., Qin Z., Jia M., Zhang C., Tian X., et al. (2019a). NUDT15 and TPMT Genetic Polymorphisms Are Related to Azathioprine Intolerance in Chinese Patients with Rheumatic Diseases. Genet. Test. Mol. Biomarkers 23, 751–757. 10.1089/gtmb.2018.0313 [DOI] [PubMed] [Google Scholar]
  51. Yang J. J., Landier W., Yang W., Liu C., Hageman L., Cheng C., et al. (2015). Inherited NUDT15 Variant Is a Genetic Determinant of Mercaptopurine Intolerance in Children with Acute Lymphoblastic Leukemia. J. Clin. Oncol. 33, 1235–1242. 10.1200/JCO.2014.59.4671 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Yang J. J., Whirl-Carrillo M., Scott S. A., Turner A. J., Schwab M., Tanaka Y., et al. (2019b). Pharmacogene Variation Consortium Gene Introduction: NUDT15. Clin. Pharmacol. Ther. 105, 1091–1094. 10.1002/cpt.1268 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Yang S. K., Hong M., Baek J., Choi H., Zhao W., Jung Y., et al. (2014). A Common Missense Variant in NUDT15 Confers Susceptibility to Thiopurine-Induced Leukopenia. Nat. Genet. 46, 1017–1020. 10.1038/ng.3060 [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Zaza G., Cheok M., Krynetskaia N., Thorn C., Stocco G., Hebert J. M., et al. (2010). Thiopurine Pathway. Pharmacogenet Genomics 20, 573–574. 10.1097/FPC.0b013e328334338f [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Zhang A. L., Yang J., Wang H., Lu J. L., Tang S., Zhang X. J. (2018). Association of NUDT15 c.415C>T Allele and Thiopurine-Induced Leukocytopenia in Asians: a Systematic Review and Meta-Analysis. Ir J. Med. Sci. 187, 145–153. 10.1007/s11845-017-1608-x [DOI] [PubMed] [Google Scholar]
  56. Zhou H., Li L., Yang P., Yang L., Zheng J. E., Zhou Y., et al. (2018). Optimal Predictor for 6-mercaptopurine Intolerance in Chinese Children with Acute Lymphoblastic Leukemia: NUDT15, TPMT, or ITPA Genetic Variants. BMC Cancer 18, 516. 10.1186/s12885-018-4398-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Zhu X., Wang X. D., Chao K., Zhi M., Zheng H., Ruan H. L., et al. (2016). NUDT15 Polymorphisms Are Better Than Thiopurine S-Methyltransferase as Predictor of Risk for Thiopurine-Induced Leukopenia in Chinese Patients with Crohn's Disease. Aliment. Pharmacol. Ther. 44, 967–975. 10.1111/apt.13796 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (801.3KB, docx)

Data Availability Statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES